Journal article
Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism
Blood, Vol.118(12), pp.3347-3349
09/22/2011
DOI: 10.1182/blood-2011-05-351411
PMCID: PMC3179401
PMID: 21768303
Abstract
Natural killer (NK) cell–mediated antibody-dependent cellular cytotoxicity involving FcγRIIIa (CD16) likely contributes to the clinical efficacy of rituximab. To assess the in vivo effects of CD16 polymorphisms on rituximab-induced NK activation, blood was evaluated before and 4 hours after initiation of the initial dose of rituximab in 21 lymphoma subjects. Rituximab induced NK activation and a drop in circulating NK-cell percentage in subjects with the high-affinity [158(VF/VV)] but not the low-affinity [158(FF)] CD16 polymorphism. There was no correlation between NK-cell activation or NK-cell percentage and polymorphisms in CD32A, C1q, or CH50. We conclude that NK activation occurs within 4 hours of rituximab infusion in subjects with the high-affinity CD16 polymorphism but not those with the low-affinity CD16 polymorphism. This finding may help explain the superior clinical outcome seen in the subset of high-affinity CD16 polymorphism lymphoma patients treated with single-agent rituximab.
Details
- Title: Subtitle
- Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism
- Creators
- Suresh Veeramani - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IASiao-Yi Wang - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IAChristopher Dahle - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IASue Blackwell - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IALaura Jacobus - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IATina Knutson - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IAAnna Button - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IABrian K Link - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IAGeorge J Weiner - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA
- Resource Type
- Journal article
- Publication Details
- Blood, Vol.118(12), pp.3347-3349
- Publisher
- American Society of Hematology
- DOI
- 10.1182/blood-2011-05-351411
- PMID
- 21768303
- PMCID
- PMC3179401
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Grant note
- P50 CA97274; R01 CA137198 / National Institutes of Health
- Language
- English
- Date published
- 09/22/2011
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Holden Comprehensive Cancer Center; Internal Medicine
- Record Identifier
- 9984094546002771
Metrics
76 Record Views